Neuroimaging Studies of the Treatment of Bipolar Depression With Citalopram

Completed

• Conditions: Bipolar Depression

• Registration Number: NCT01639482
• Lead Sponsor: Massachusetts General Hospital

Brief Summary

Regional metabolic changes associated with response to 6 weeks of citalopram treatment, using 18-Fluorodeoxyglucose Positron Emission Tomography imaging, will be characterized (FDG PET).

Detailed Description

Regional metabolic changes associated with response to 6 weeks of citalopram treatment, using 18-Fluorodeoxyglucose Positron Emission Tomography imaging, will be characterized (FDG PET). The following hypothesis will be tested: Antidepressant response or remission in depressed BPD patients will be associated with changes in cortical (prefrontal, parietal, premotor) and paralimbic (hippocampus, anterior cingulate, subgenual cingulate, posterior cingulate, and anterior insula) regions, consistent with SRI antidepressant response in unipolar depressed patients.

Study Timeline

• Study Start: 2010-04
• Study First Submitted: 2012-07-10
• Study First Submitted QC: 2012-07-10
• Study First Posted: 2012-07-12
• Primary Completion: 2013-12
• Study Completion: 2013-12
• Status Verified: 2019-03
• Last Update Submitted: 2019-03-05
• Last Update Posted: 2019-03-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Current age 18-64 years; DSM-IV diagnosis of BPD, type-I, or type-II; Enrolled in the Citalopram Study at Tufts Medical Center

Exclusion Criteria

• Current pregnancy, or inability to utilize contraception, The presence of any metallic implants, History of claustrophobia

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
rCMRglu	pre and post-treatment	regional glucose metabolism

Trial Locations

Locations (1)

Massachusetts General Hospital - East; 🇺🇸 Charlestown, Massachusetts, United States